390 related articles for article (PubMed ID: 22390313)
21. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
[TBL] [Abstract][Full Text] [Related]
24. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.
Gondek LP; Tiu R; O'Keefe CL; Sekeres MA; Theil KS; Maciejewski JP
Blood; 2008 Feb; 111(3):1534-42. PubMed ID: 17954704
[TBL] [Abstract][Full Text] [Related]
27. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Haematologica; 2009 Dec; 94(12):1762-6. PubMed ID: 19797731
[TBL] [Abstract][Full Text] [Related]
28. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
29. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
31. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
Olney HJ; Le Beau MM
Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
[TBL] [Abstract][Full Text] [Related]
33. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
[TBL] [Abstract][Full Text] [Related]
34. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
Sun Y; Cook JR
Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
[TBL] [Abstract][Full Text] [Related]
35. Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
Jann JC; Nowak D; Nolte F; Fey S; Nowak V; Obländer J; Pressler J; Palme I; Xanthopoulos C; Fabarius A; Platzbecker U; Giagounidis A; Götze K; Letsch A; Haase D; Schlenk R; Bug G; Lübbert M; Ganser A; Germing U; Haferlach C; Hofmann WK; Mossner M
J Med Genet; 2017 Sep; 54(9):640-650. PubMed ID: 28600436
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
[TBL] [Abstract][Full Text] [Related]
38. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z
Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289
[TBL] [Abstract][Full Text] [Related]
40. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]